Andre Goy, MD, discusses the agents he finds most promising for the treatment of patients with mantle cell lymphoma.
Andre Goy, MD, chief in the division of lymphoma, chairman and director at John Theurer Cancer Center, discusses the agents he finds promising for the treatment of patients with mantle cell lymphoma (MCL).
BTK inhibitors such as rituximab (Rituxan) have been impressive in the salvage setting, according to Goy. Triplet combinations with venetoclax and ibrutinib in this setting also look like they will move to the frontline for treatment of patients with MCL.
In addition, data for rituximab, bendamustine, and cytarabine (R-BAC) appear impressive in the frontline even when the dose of cytarabine is adjusted in elderly patients. Goy also highlights the importance of doing full pathology, as well as checking for the ECOG status and p53 status.
See more fromthis interview on MCL here
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More
Landgren on MRD as an End Point for Multiple Myeloma Trials
May 1st 2024C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.
Read More